scholarly journals Virus–host interactions in carcinogenesis of Epstein-Barr virus-associated gastric carcinoma: Potential roles of lost ARID1A expression in its early stage

PLoS ONE ◽  
2021 ◽  
Vol 16 (9) ◽  
pp. e0256440
Author(s):  
Hiroyuki Abe ◽  
Akiko Kunita ◽  
Yuya Otake ◽  
Teru Kanda ◽  
Atsushi Kaneda ◽  
...  
Keyword(s):  
Gastric Mucosa ◽  
Epithelial Cells ◽  
Gastric Carcinoma ◽  
Epstein Barr Virus ◽  
Cancer Tissue ◽  
Host Interactions ◽  
Barr Virus ◽  
Epstein Barr

Epstein–Barr virus (EBV)-associated gastric carcinoma (EBVaGC) is a distinct molecular subtype of gastric cancer characterized by viral infection and cellular abnormalities, including loss of AT-rich interaction domain 1A (ARID1A) expression (lost ARID1A). To evaluate the significance of lost ARID1A in the development of EBVaGC, we performed in situ hybridization of EBV-encoded RNA (EBER) and immunohistochemistry of ARID1A in the non-neoplastic gastric mucosa and intramucosal cancer tissue of EBVaGC with in vitro infection analysis of ARID1A-knockdown and -knockout gastric cells. Screening of EBER by in situ hybridization revealed a frequency of approximately 0.2% EBER-positive epithelial cells in non-neoplastic gastric mucosa tissue samples. Six small foci of EBV-infected epithelial cells showed two types of histology: degenerated (n = 3) and metaplastic (n = 3) epithelial cells. ARID1A was lost in the former type. In intramucosal EBVaGC, there were ARID1A-lost (n = 5) and -preserved tumors (n = 7), suggesting that ARID1A-lost carcinomas are derived from ARID1A-lost precursor cells in the non-neoplastic mucosa. Lost ARID1A was also observed in non-neoplastic mucosa adjacent to an ARID1A-lost EBVaGC. In vitro experiments using siRNA knockdown and the CRISPR/Cas9-knockout system demonstrated that transient reduction or permanent loss of ARID1A expression markedly increased the efficiency of EBV infection to stomach epithelial cells. Taken together, lost ARID1A plays a role in initiating EBV-driven carcinogenesis in stomach epithelial cells, which develop to a distinct subtype of EBVaGC within the proper mucosal layer. Lost ARID1A is one of the constituents of virus–host interactions in the carcinogenesis of EBVaGC.

scholarly journals Epstein-Barr virus-associated gastric carcinoma in Brazil: comparison between in situ hybridization and polymerase chain reaction detection

2012 ◽  
Vol 43 (1) ◽  
pp. 393-404 ◽  
Author(s):  
Marcos Antonio Pereira de Lima ◽  
Márcia Valéria Pitombeira Ferreira ◽  
Marcos Aurélio Pessoa Barros ◽  
Maria Inês de Moura Campos Pardini ◽  
Adriana Camargo Ferrasi ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
In Situ Hybridization ◽  
Gastric Carcinoma ◽  
Epstein Barr Virus ◽  
Polymerase Chain Reaction Detection ◽  
Chain Reaction ◽  
Barr Virus ◽  
Polymerase Chain ◽  
Epstein Barr

scholarly journals Epstein-Barr Virus WZhet DNA Can Induce Lytic Replication in Epithelial Cells in vitro, although WZhet Is Not Detectable in Many Human Tissues in vivo

Intervirology ◽  
2009 ◽  
Vol 52 (1) ◽  
pp. 8-16 ◽  
Author(s):  
Julie L. Ryan ◽  
Richard J. Jones ◽  
Sandra H. Elmore ◽  
Shannon C. Kenney ◽  
George Miller ◽  
...  
Keyword(s):  
Epithelial Cells ◽  
Epstein Barr Virus ◽  
Lytic Replication ◽  
Human Tissues ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals X-Linked Agammaglobulinemia Patients Are Not Infected with Epstein-Barr Virus: Implications for the Biology of the Virus

1999 ◽  
Vol 73 (2) ◽  
pp. 1555-1564 ◽  
Author(s):  
Glenda C. Faulkner ◽  
Scott R. Burrows ◽  
Rajiv Khanna ◽  
Denis J. Moss ◽  
A. Graham Bird ◽  
...  
Keyword(s):  
Epithelial Cells ◽  
B Lymphocytes ◽  
Epstein Barr Virus ◽  
Human Herpesvirus ◽  
Infection Process ◽  
Barr Virus ◽  
Epstein Barr ◽  
Memory Cytotoxic T Lymphocytes

ABSTRACT Epstein-Barr virus (EBV) infects both B lymphocytes and squamous epithelial cells in vitro, but the cell type(s) required to establish primary and persistent infection in vivo has not been definitively elucidated. The aim of this study was to investigate a group of individuals who lack mature B lymphocytes due to the rare heritable disorder X-linked agammaglobulinemia in order to determine the role of the B cell in the infection process. The results show that none of these individuals harbored EBV in their blood or throat washings. Furthermore, no EBV-specific memory cytotoxic T lymphocytes were found, suggesting that they had not undergone infection in the past. In contrast, 50% of individuals were found to carry human herpesvirus 6, showing that they are infectible by another lymphotropic herpesvirus. These results add weight to the theory that B lymphocytes, and not oropharyngeal epithelial cells, may be required for primary infection with EBV.

scholarly journals Epithelial Cell Adhesion to Extracellular Matrix Proteins Induces Tyrosine Phosphorylation of the Epstein-Barr Virus Latent Membrane Protein 2: a Role for C-Terminal Src Kinase

1999 ◽  
Vol 73 (6) ◽  
pp. 4767-4775 ◽  
Author(s):  
Frank Scholle ◽  
Richard Longnecker ◽  
Nancy Raab-Traub
Keyword(s):  
Cell Adhesion ◽  
Epithelial Cells ◽  
Tyrosine Phosphorylation ◽  
Epstein Barr Virus ◽  
Latent Membrane Protein ◽  
Src Family Kinases ◽  
Barr Virus ◽  
Epstein Barr ◽  
Latent Membrane Protein 2

ABSTRACT The Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) is expressed in latently EBV-infected B cells, where it forms patches in the plasma membrane and interferes with B-cell receptor signal transduction through dominant-negative effects on protein kinases. LMP2 transcripts are detected in nasopharyngeal carcinoma, an epithelial-cell malignancy. In this study the function of LMP2A in epithelial cells was investigated. LMP2A was found to coprecipitate with protein kinase activities and to become phosphorylated in in vitro kinase assays. Analysis of LMP2A deletion mutants demonstrated that tyrosines implicated in interacting with Src family kinase SH2 domains and the SH2 domain of Csk, as well as the LMP2A immunoreceptor tyrosine-based activation motif, are important for its phosphorylation in epithelial cells. LMP2A tyrosine phosphorylation was triggered by cell adhesion to extracellular-matrix (ECM) proteins. Src family kinases, whose involvement in cell-ECM signaling and LMP2A phosphorylation in B lymphocytes has been well established, were found not to be responsible for LMP2A phosphorylation in epithelial cells. Instead, coexpression of Csk, a negative Src regulator, and LMP2A led to an increase in LMP2A phosphorylation both in nonadherent cells and upon cell adhesion. Csk also phosphorylated LMP2A in vitro. These results suggest that LMP2A has a different role in epithelial cells, where it interacts with cell adhesion-initiated signaling pathways. Although tyrosine phosphorylation of LMP2A occurs in both cell types, different protein kinases seem to be used: Src family kinases in B lymphocytes and Csk in epithelial cells.

scholarly journals Epstein-Barr virus and gastric carcinoma: virus-host interactions leading to carcinoma

2008 ◽  
Vol 99 (9) ◽  
pp. 1726-1733 ◽  
Author(s):  
Masashi Fukayama ◽  
Rumi Hino ◽  
Hiroshi Uozaki
Keyword(s):  
Gastric Carcinoma ◽  
Epstein Barr Virus ◽  
Host Interactions ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Features Distinguishing Epstein-Barr Virus Infections of Epithelial Cells and B Cells: Viral Genome Expression, Genome Maintenance, and Genome Amplification

2009 ◽  
Vol 83 (15) ◽  
pp. 7749-7760 ◽  
Author(s):  
Claire Shannon-Lowe ◽  
Emily Adland ◽  
Andrew I. Bell ◽  
Henri-Jacques Delecluse ◽  
Alan B. Rickinson ◽  
...  
Keyword(s):  
B Cells ◽  
Epithelial Cells ◽  
Viral Genome ◽  
Epstein Barr Virus ◽  
Lytic Cycle ◽  
Ags Cells ◽  
Barr Virus ◽  
Genome Expression ◽  
Epstein Barr

ABSTRACT Epstein-Barr virus (EBV) is associated with malignant diseases of lymphoid and epithelial cell origin. The tropism of EBV is due to B-cell-restricted expression of CD21, the major receptor molecule for the virus. However, efficient infection of CD21− epithelial cells can be achieved via transfer from EBV-coated B cells. We compare and contrast here the early events following in vitro infection of primary B cells and epithelial cells. Using sensitive, quantitative reverse transcription-PCR assays for several latent and lytic transcripts and two-color immunofluorescence staining to analyze expression at the single cell level, we confirmed and extended previous reports indicating that the two cell types support different patterns of transcription. Furthermore, whereas infection of B cells with one or two copies of EBV resulted in rapid amplification of the viral genome to >20 copies per cell, such amplification was not normally observed after infection of primary epithelial cells or undifferentiated epithelial lines. In epithelial cells, EBNA1 expression was detected in only ca. 40% of EBER+ cells, and the EBV genome was subsequently lost during prolonged culture. One exception was that infection of AGS, a gastric carcinoma line, resulted in maintenance of EBNA1 expression and amplification of the EBV episome. In contrast to B cells, where amplification of the EBV episome occurred even with a replication-defective BZLF1-knockout virus, amplification in AGS cells was dependent upon early lytic cycle gene expression. These data highlight the influence of the host cell on the outcome of EBV infection with regard to genome expression, amplification, and maintenance.

scholarly journals Novel Therapeutics for Epstein–Barr Virus

Molecules ◽  
2019 ◽  
Vol 24 (5) ◽  
pp. 997 ◽  
Author(s):  
Graciela Andrei ◽  
Erika Trompet ◽  
Robert Snoeck
Keyword(s):  
B Cells ◽  
Epithelial Cells ◽  
Epstein Barr Virus ◽  
Adult Population ◽  
Antiviral Drug ◽  
Barr Virus ◽  
Epstein Barr ◽  
New Strategies

Epstein–Barr virus (EBV) is a human γ-herpesvirus that infects up to 95% of the adult population. Primary EBV infection usually occurs during childhood and is generally asymptomatic, though the virus can cause infectious mononucleosis in 35–50% of the cases when infection occurs later in life. EBV infects mainly B-cells and epithelial cells, establishing latency in resting memory B-cells and possibly also in epithelial cells. EBV is recognized as an oncogenic virus but in immunocompetent hosts, EBV reactivation is controlled by the immune response preventing transformation in vivo. Under immunosuppression, regardless of the cause, the immune system can lose control of EBV replication, which may result in the appearance of neoplasms. The primary malignancies related to EBV are B-cell lymphomas and nasopharyngeal carcinoma, which reflects the primary cell targets of viral infection in vivo. Although a number of antivirals were proven to inhibit EBV replication in vitro, they had limited success in the clinic and to date no antiviral drug has been approved for the treatment of EBV infections. We review here the antiviral drugs that have been evaluated in the clinic to treat EBV infections and discuss novel molecules with anti-EBV activity under investigation as well as new strategies to treat EBV-related diseases.

Sign in / Sign up

Export Citation Format

Share Document